Metabolic syndrome X and ischaemic heart disease;Metabolický syndróm X a ischemická choroba srdca

Kardiologia

Volumn 14, Issue 5, 2005, Pages 231-235

  Mikeš, Zoltán ^a  

^a Klinika Geriatrie   (Slovakia)

Author keywords

Atherosclerosis; Chronic inflammation; Endothelial dysfunction; Ischaemic heart disease; Metabolic syndrome X; Risk factors

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD PRESSURE MEASUREMENT; CORONARY ARTERY DISEASE; DYSLIPIDEMIA; ENDOTHELIUM; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; METABOLIC SYNDROME X; OBESITY; OXIDATION; RISK FACTOR; WAIST CIRCUMFERENCE;

EID: 26944494073     PISSN: 12100048     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Reaven GM. Banting Lecture 1988: role of insulin resistance in human disease. Diabetes 1988;37:1595-1607.
2. Meigs JB. Epidemiology of the insulin resistance syndrome. Curr Diab Rep 2003;3:73-79.
3. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham Study. J Am Med Ass 1979;241:2035-2038.
4. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Europ Heart J 2003;24:1601-1610.
5. Ninomiya JK, L'Italien G, Criqui MH, et al. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation 2004;109:42-46.
6. McNeill AM, Girman CJ, et al. Prevalence of Coronary Heart Disease and Carotid Arterial Thickening in Patients With the Metabolic Syndrome (The ARIC Study). Am J Cardiol 2004; 94:1249-1254.
7. Scandinavian Simvastatin Survival Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study. Lancet 1994;344:1383-1389.
8. The HOPE study investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-153.
9. Fox KM, Bertrand M, Ferrari R, et al. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-788.
10. Pyoräla K, Ballantyne ChM, Gumbiner B, et al. Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: Subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 2004;27:1735-1740.
11. Gordon NF, Salmon RD, Franklin BA, et al. Effectiveness of therapeutic lifestyle changes in Patients with hypertension, hyperlipidemia, and/or hyperglycemia. Am J Cardiol 2004;94:1558-1561.
12. Rigby N. Obesity: the major threat to public health? Heart Beat 2002;3:1-2.
13. World Health Organization. Obesity: preventing and managing the global epidemic. Report of WHO consultation. WHO Technical Report Series. Geneva: WHO 2000:86.
14. Dixon JB, O'Brian PE. Lipid profile in the severely obese. Obesity Res 2002;10:903-909.
15. Maki KC. Dietary factors in the prevention of diabetes mellitus and coronary artery disease associated with the metabolic syndrome. Am J Cardiol 2004;93(Suppl):12C-17C.
16. Ryder JW, Gilbert M, Zierath JR. Skeletal muscle and insulin sensitivity; pathophysiological alterations. Front Biosci 2001;6:153-163.
17. Shirai K. Obesity as the core of the metabolic syndrome and the management of coronary heart disease. Current Medical Research & Opinion 2004;20:295-304.
18. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000;11:327-332.
19. Doelle, Gregory C. The clinical picture of metabolic syndrome. Postgraduate Medicine 2004;116:5432-5481.
20. Mohamed-Ali V, Goodrick S, Bulmer K, et al. Production of soluble tumor necrosis factor receptors by human subcutaneous adipose tissue in vivo. Am J Physiol 1999;277:E 971-975.
21. White MF, Maron R, Kahn CR. Insulin rapidly stimulates tyrosine phosphorylation of a Mr-185,000 protein in intact cells. Nature 1985;318:183-186.
22. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001;409:307-312.
23. Huang Z. Body weight, weight change, and risk for hypertension in women. Ann Intern Med 1998;128:81-88.
24. Dixon JB, O'Brian PE. Lipid profile in the severely obese. Obesity Res 2002;10:903-909.
25. Tkáč I. Vztah metabolického syndrómu k rozvoju diabetes mellitus 2. typu a aterosklerózy. Cardiol 2005; 14:133-137.
26. Grossman E, Messerli FH. Diabetic and hypertensive heart disease. Ann Intern Med 1996;125:304-310.
27. Mazzone T. Strategies in ongoing clinical trials to reduce cardiovascular disease in patients with diabetes mellitus and insulin resistance. Am J Cardiol 2004;93(11A):27C-31C.
28. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol.1974;34:29-34.
29. Reilly MP, Wolfe ML, Rhodes T, et al. Measures of insulin resistance add incremental value to the clinical diagnosis of metabolic syndrome in association with coronary atherosclerosis. Circulation 2004;110:803-809.
30. Kalme T, Seppala M, Qiao Q, et al. Sex hormone-binding globulin and insulin-like growth factor-binding protein-1 as indicators of metabolic syndrome, cardiovascular risk, and mortality in elderly men. Journal of Clinical Endocrinology & Metabolism, 2005;90:1550-1556.
31. van Hoeven KH, Factor SM. A comparison of the pathological spectrum of hypertensive, diabetic, and hypertensive-diabetic heart disease. Circulation 1990;82:848-855.
32. Orlander PR, Goff DC,Morrissey M, et al. The relation of diabetes to the severity of acute myocardial infarction and post-myocardial infarction survival in Mexican-Americans and non-Hispanic whites. The Corpus Christi Heart Project. Diabetes 1994;43:897-902.
33. Becker A, Bos G, de Vegt F, et al. Cardiovascular events in type 2 diabetes: comparison with nondiabetic individuals without and with prior cardiovascular disease. 10 year follow-up of the Hoorn Study. Europ Heart J 2003;24:1406-1413.
34. Fábryová L. Aterogénna dyslipidémia - súčast metabolického syndrómu. Cardiol 2005; 14:124-130.
35. MacRury SM, Lowe GD. Blood rheology in diabetes mellitus. Diabetic Med 1990;7:285-291.
36. Niakan E, Harati Y, Rolak LA, et al. Silent myocardial infarction and diabetic cardiovascular autonomic neuropathy. Arch Int Med 1986;146:2229-2230.
37. Biondi-Zoccai GL, Abbate A, Liuzzo G, et al. Atherothrombosis, inflammation and diabetes. J Am Coll Cardiol 2003;41:1070-1077.
38. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet 1997;350:430-436.
39. Furchgott RF, Zawadski JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288:373-376.
40. Lim SC, Caballero AE, Smakowski P, et al. Soluble intercellular adhesion molecule, vascular cell adhesion molecule,and impaired microvascular reactivity are early markers of vasculopathy in type 2 diabetic individuals without microalbuminuria. Diabetes Care 1999;22:1865-1870.
41. Ziccardi P, Nappo F, Giugliano G, et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year Circulation 2002; 105:804-809.
42. Clarkson P, Celermajer DS, Powe AJ, et al. Endothelium-dependent dilatation is impaired in young healthy subjects with a family history of premature coronary disease. Circulation 1997;96:3378-3383.